Feasibility of the AML profiler Skyline (TM) Array) for patient risk stratification in a multicentre trial: a preliminary comparison with the conventional approach
Por:
Nomdedeu, JF, Puigdecanet, E, Bussaglia, E, Hernandez, JJ, Carricondo, M, Estivill, C, Marti-Tutusaus, JM, Tormo, M, Zamora, L, Serrano, E, Perea, G, de Llano, MPQ, Garcia, A, Sanchez-Ortega, I, Ribera, JM, Nonell, L, Aventin, A, Sole, F, Brunet, MS, Sierra, J
Publicada:
1 dic 2017
Resumen:
Deoxyribonucleic acid microarrays allow researchers to measure mRNA levels of thousands of genes in a single experiment and could be useful for diagnostic purposes in patients with acute myeloid leukaemia (AML). We assessed the feasibility of the AML profiler (Skyline (TM) Array) in genetic stratification of patients with de novo AML and compared the results with those obtained using the standard cytogenetic and molecular approach.Diagnostic bone marrow from 31 consecutive de novo AML cases was used to test MLL-PTD, FLT3-ITD and TKD, NPMI and CEBPAdm mutations. Purified RNA was used to assess RUNX1-RUNXITI, PML-RARa and CBF beta-MYII11 rearrangements. RNA remnants underwent gene expression profiling analysis using the AML profiler, which detects chromosomal aberrations: t(8;21), t(15;17), inv(16), mutations (CEBPAdm, ABD-NPMI) and BAALC and EVIL expression. Thirty cases were successfully analysed with both methods. Five cases had FLT3-ITD. In one case, a t(8;21) was correctly detected by both methods. Four cases had inv(16); in one, the RNA quality was unsatisfactory , and it was not hybridized, and in the other three, the AML profiler detected the genetic lesion - this being a rare type I translocation in one case. Two cases with acute promyelocytic leukaemia were diagnosed by both methods. Results for NPMI mutations were concordant in all but two cases (2/11, non-ABD mutations). Analysis of costs and turnaround times showed that the AML profiler was no more expensive than the conventional molecular approach. These results suggest that the AML profiler could be useful in multicentre trials to rapidly identify patients with AML with a good prognosis. Copyright (C) 2016 John Wiley & Sons, Ltd.
Filiaciones:
Nomdedeu, JF:
Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain
Puigdecanet, E:
IMIM Hosp Mar Med Res Inst, Serv Anal Microarrays, Barcelona, Spain
Bussaglia, E:
Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain
Hernandez, JJ:
Lab Referencia Catalunya, Barcelona, Spain
Carricondo, M:
Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain
Estivill, C:
Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain
Marti-Tutusaus, JM:
Hosp Univ Mutua de Terrassa, Dept Hematol, Barcelona, Spain
Tormo, M:
Hosp Clinico Valencia, Dept Hematol, INCLIVA, Valencia, Spain
Zamora, L:
ICO Badalona Hosp Germans Trias & Pujol, Inst Recerca Leucemia Josep Carreras IJC, Dept Hematol, Badalona, Spain
Serrano, E:
IIB St Pau, Bioinformat Platform, Barcelona, Spain
Perea, G:
Parc Tauli Hosp Univ, Lab Serv, UDIAT CD, Sabadell, Spain
de Llano, MPQ:
Hosp Virgen de la Victoria, Dept Hematol, Malaga, Spain
Garcia, A:
Hosp Arnau Vilanova, Dept Hematol, Lleida, Spain
Sanchez-Ortega, I:
Bellvitge Hosp, Dept Hematol, Lhospitalet De Llobregat, Spain
Ribera, JM:
ICO Badalona Hosp Germans Trias & Pujol, Inst Recerca Leucemia Josep Carreras IJC, Dept Hematol, Badalona, Spain
Nonell, L:
IMIM Hosp Mar Med Res Inst, Serv Anal Microarrays, Barcelona, Spain
Aventin, A:
Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain
Sole, F:
ICO Badalona Hosp Germans Trias & Pujol, Inst Recerca Leucemia Josep Carreras IJC, Dept Hematol, Badalona, Spain
Brunet, MS:
Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain
Sierra, J:
Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain
|